Case Report:
A new born male baby, first issue of his nonconsanguineous parents presented with a large sized hemangioma on his right upper extremity and small hemangioma on the neck and on parietal region of the scalp. Baby was born before term at 30 th weeks of gestation by LUCS due to pre-mature rupture of the membrane. His mother was 25 year-old-lady with good general health and was on regular antenatal checkup. There was no family history of similar illness.
On examination baby was pre term, very low birth weight 1.25kg with large, solitary 20cmX10cm sized erythematous induration on the right upper extremity. Two other indurations were noted on the neck (3x2cm sized) and parietal region of the scalp (2x1cm sized). These lesions were diagnosed as hemangioma.
The initial laboratory data revealed normocytic normochromic anaemia(Hb% 10.5gm/dl), thrombocytopenia (Platelet count 80,000/cumm of blood). Other laboratory results including WBC counts, bleeding time, clotting time, activated partial thromboplastin time (APTT), prothombin time were within the normal range. Patient was diagnosed as Kasabach Merritt syndrome from a pre-existing hemangioma, clinical findings and laboratory values.
Baby was managed with blood transfusion and oral prednisolone. Seven days after initiating treatment his platelet count was increased and lesion ceased to expand. Then dose of the prednisolone was subsequently tapered.
Discussion:
Haemangioma is a commonly encountered benign vascular neoplasm. It is the most common soft tissue neoplasm of infancy 5 . KMS is a coagulopathy consisting of intravascular coagulation, clotting and fibrinolysis within the haemangioma. The trigger factors for the development of KMS include surgical intervention, pregnancy, angiography and needle aspiration of haemangioma [6] [7] [8] .
The pathogenesis of KMSin yet to be established. However, platelet trapping by abnormally proliferating endothelium within the haemangioma has been proposed as a possible mechanism 9 . Platelet trapping can result in the activation of platelets with secondary activation of coagulation cascades, eventually leading to consumption of various clotting factors. In addition to platelet trapping, excessive blood flow and sheer stress secondary to arteriovenous shunts within the tumor may cause further platelet activation. Both thrombocytopenic status and reduction in coagulation factors eventually result in bleeding within the tumors that manifests as a rapidly growing hemangioma.
Management of KMS has been challenging because of its rarity and there are no well established systemic treatment strategies. Systemic corticosteroid is considered to be first line therapy in patients with KMS [10] [11] [12] . If a lesion responds to steroid, the dose should be reduced slowly to prevent recurrence. The mechanism of prednisolone in controlling thrombocytopenia, coagulopathy and stabilization of hemangiomas remain unclear, although it appears to increase platelet, increase vasoconstriction, inhibit fibrinolysis and disrupt angiogenesis.
In cases resistant to systemic corticosteroid, multiple treatment modalities can be used in a stepwise manner, including interferon-alpha, an antiproliferative and antiangiogenic agent and vincristine, a strong inhibitor of angiogenesis. Radiotherapy is another option which can induce embolization within the hemangioma. These options are usually recommended as second line therapies 9-12. 
